JAAD Case Reports · 2020 · 26 citations · 4 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMetastasisAntidotal TherapyDermatologic Toxicity ManagementGenitourinary Cancer PharmacotherapyMalignant NeoplasmsMetastatic Disease TreatmentToxicity ManagementChemotherapy-induced Dermatologic ToxicityEarly-phase Clinical TrialsPeripheral Neuropathy PharmacotherapyProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 InhibitorsTherapeutic ToxicityThird-line ChemotherapyThird-line Treatment
Enfortumab vedotin is a novel treatment for metastatic urothelial carcinoma. In 2019, the United States Food and Drug Administration approved the drug as a third-line treatment for patients who had failed in previous trials of programmed cell death protein 1 and platinum-based chemotherapeutic agents.1 The drug has demonstrated to have a significant response rate in early phase trials and is known for its tolerable side-effect profile.2 The adverse effects of enfortumab vedotin include fatigue, peripheral neuropathy, alopecia, and rash.
4
Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2019 · 626 citations · Full text
Medicine, Oncology, Pharmacology +17